Skip to main content

Table 1 Clinicopathological characteristics of the patients

From: Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial

ID

Age

Liver cirrhosis

HBV

HCV

Alcohol abuse

Other

Number of lesions (> 20 = DD)

Max. diameter largest lesion (mm)

PVI

CP

CP points

BCLC stage

Therapy

M

R

death

OS (months)

A

46

No

Neg

Neg

No

Nash

28

34

No

A

5

C

RE

SRFB

No

No

0

40.7

B

60

No

Neg

Neg

No

–

99

160

No

A

6

C

RE

SRFB

Yes

No

1

38.6

C

61

No

Neg

Neg

No

Nash

99

8

No

A

5

B

RE

SRFB

No

No

0

23.4

D

61

No

Neg

Neg

No

Nash

na

88

No

A

5

B

RE

SRFB

No

No

0

16.1

E

59

No

Neg

pos

No

–

na

55

Yes

A

5

C

RE

SRFB

Yes

No

1

11.7

F

68

Yes

Neg

Neg

Yes

Nash

3

91

Yes

A

6

C

RE

SRFB

Yes

No

1

26.8

G

75

Yes

Neg

Neg

Yes

–

na

na

No

A

6

B

RE

SRFB

No

No

1

13.7

H

68

Yes

Neg

Neg

Yes

–

3

15

Yes

A

5

C

RE

SRFB

No

No

1

16.8

I

66

Yes

Neg

Neg

Yes

–

na

65

No

A

5

C

RE

SRFB

Yes

No

1

13.0

J

69

Yes

Neg

Neg

Yes

–

2

75

No

A

5

B

RE

SRFB

No

No

1

17.5

K

70

Yes

Neg

Neg

Yes

–

1

43

No

A

5

A

RFA

PLC

No

Yes

1

27.1

L

82

Yes

Neg

Neg

Yes

–

1

40

No

A

6

A

RFA

SRFB

No

No

1

26.3

M

73

Yes

Neg

Neg

Yes

–

1

33

No

A

5

A

RFA

SRFB

No

Yes

1

32.5

  1. HBV, hepatitis B virus; HCV, hepatitis C virus; DD, diffuse disease; Nash, non-alcoholic steatohepatitis; PVI, portal vein infiltration; CP, Child–Pugh, BCLC, Barcelona Clinic Liver Cancer; RE, 90Y-Radioembolization; SRFB, sorafenib; PLCB, placebo; M, metastases; R, recurrence; OS, overall survival, in months; na, not available